

Andrew Freistein 10/786,710

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptabf1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records  
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right truncation  
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced  
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine  
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme  
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 13 OCT 19 E-mail format enhanced  
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available  
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases  
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded  
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced  
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available  
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role  
NEWS 22 NOV 20 CAS Registry Number crossover limit increased to 300,000 in additional databases  
NEWS 23 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000  
NEWS 24 NOV 20 CA/CAplus patent kind codes will be updated  
NEWS 25 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 26 DEC 11 CAS REGISTRY chemical nomenclature enhanced

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Andrew Freistein 10/786,710

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:01:29 ON 13 DEC 2006

FILE 'REGISTRY' ENTERED AT 13:01:50 ON 13 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 DEC 2006 HIGHEST RN 915277-53-1  
DICTIONARY FILE UPDATES: 12 DEC 2006 HIGHEST RN 915277-53-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10786710\d.str



chain nodes :

19 20 21 22 23 24 25 26 27 28 29 30 32 33 34 35

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-20 2-32 10-19 13-29 14-28 15-21 16-22 17-23 18-27 21-24 21-25 23-26  
23-30 32-33 33-34 33-35

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13  
12-15 13-14 13-18 15-16 16-17 17-18

exact/norm bonds :

1-20 2-32 5-7 6-10 7-8 8-9 8-11 9-10 9-14 10-19 11-12 12-13 12-15  
13-14 13-18 13-29 14-28 15-16 15-21 16-17 16-22 17-18 17-23 18-27 21-24  
21-25 23-26 23-30 32-33 33-34 33-35

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

G2:O,S


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS  
12/13/2006 29:CLASS 30:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS

Andrew Freistein 10/786,710

L1 STRUCTURE UPLOADED

=> d  
L1 HAS NO ANSWERS  
L1 STR



G1 C,O,S,N

G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 13:02:11 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3 TO 163  
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s 11 full  
FULL SEARCH INITIATED 13:02:15 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 73 TO ITERATE

100.0% PROCESSED 73 ITERATIONS 55 ANSWERS  
SEARCH TIME: 00.00.01

L3 55 SEA SSS FUL L1

=> file hcaplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL

Andrew Freistein 10/786, 710

FULL ESTIMATED COST	ENTRY 166.94	SESSION 167.15
---------------------	-----------------	-------------------

FILE 'HCAPLUS' ENTERED AT 13:02:17 ON 13 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Dec 2006 VOL 145 ISS 25  
FILE LAST UPDATED: 12 Dec 2006 (20061212/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13
L4          17 L3
=> d ibib hitstr 1-17
```

L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:1036703 HCAPLUS  
 DOCUMENT NUMBER: 141:420412  
 TITLE: Substituted tetracycline compounds for the treatment  
 of malaria  
 INVENTOR(S): Draper, Michael; Nelson, Mark L.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 590 pp., Cont.-in-part of U.S.  
 Ser. No. 128,990, abandoned.  
 CODEN: USXACO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242548	A1	20041202	US 2003-692563	20031024
US 2004052490	A1	20040513	US 2002-128990	20020424
			US 2001-286193P	P 20010424
			US 2002-128990	B2 20020424
			US 2002-421259P	P 20021024

PRIORITY APPLN. INFO.:


OTHER SOURCE(S): MARPAT 141:420412  
 IT 365277-03-8 365277-04-9 365277-05-0  
 365277-06-1 365277-07-2 365277-23-2  
 365277-24-3 365277-34-5 365277-35-6  
 365277-36-7 365277-38-9 365277-58-3  
 365277-59-4 365277-60-7 365277-61-8  
 365277-63-0 365277-64-1 365277-65-2  
 458909-96-2 460070-76-2 460073-80-7  
 473974-75-3 473974-76-4 488817-33-0  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (substituted tetracycline compds. for treatment of malaria)  
 RN 365277-03-8 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




Absolute stereochemistry.




Absolute stereochemistry.


L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



Absolute stereochemistry.




Absolute stereochemistry.




12/13/2006

L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



Page 6


L4 ANSWER 1 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 5-methyl-10,12-dioxo-2-naphthacenyl)-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-38-9 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 1 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 365277-61-8 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-63-0 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 3-butenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-64-1 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 365277-58-3 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-59-4 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-60-7 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 365277-65-2 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459809-96-2 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-  
 10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 460070-76-2 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-80-7 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473974-75-3 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473974-76-4 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064728	A2	20040805	WO 2004-US1036	20040116
WO 2004064728	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
US 2006194773	A1	20060831	US 2004-996119	20041122
PRIORITY APPLN. INFO.:			US 2003-441141P	P 20030116
			US 2001-305546P	P 20010713
			US 2002-395741P	P 20020712
			US 2002-196010	A2 20020715
			US 2004-759484	B1 20040116



RN 488817-33-0 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-04-9 HCPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthalenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-05-0 HCPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthalenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-06-1 HCPLUS

L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-22-1 HCAPLUS  
 CN Cholest-5-en-3-ol (3H)-, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]carbamate (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 365277-23-2 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-24-3 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 365277-34-5 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-35-6 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-36-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 365277-38-9 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-58-3 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-59-4 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
Absolute stereochemistry.

(Continued)




RN 365277-60-7 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-61-8 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-63-0 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, i-Bu ester (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460070-76-2 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460073-80-7 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473974-75-3 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

12/13/2006


L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-but enyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-64-1 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-65-2 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459809-96-2 HCAPLUS


L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473974-76-4 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488017-33-0 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:371069 HCAPLUS  
 DOCUMENT NUMBER: 140:386006  
 TITLE: Substituted tetracycline compounds for the treatment of malaria  
 INVENTOR(S): Draper, Michael; Nelson, Mark L.  
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 161 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038001	A2	20040506	WO 2003-US33927	20031024
WO 2004038001	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, A2, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502464	AA	20040506	CA 2003-2502464	20031024
AU 2003287218	A1	20040513	AU 2003-781398	20031024
EP 1556007		20050727	EP 2003-781398	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503898	T2	20060202	JP 2004-547165	20031024
PRIORITY APPLN. INFO.:			JP 2002-421259P	P 20021024
			WO 2003-US33927	W 20031024

OTHER SOURCE(S): MARPAT 140:386006

IT 365277-03-8 365277-04-9 365277-05-0

365277-06-1 365277-07-2 365277-23-2

365277-24-3 365277-34-5 365277-35-6

365277-36-7 365277-38-9 365277-58-3

365277-59-4 365277-60-7 365277-61-8

365277-63-0 365277-64-1 365277-65-2

459809-96-2 460070-76-2 460073-80-7

473974-75-3 473974-76-4 488817-33-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline derivs. for malaria treatment)


RN 365277-03-8 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 365277-06-1 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-07-2 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-23-2 HCAPLUS


CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

12/13/2006

L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 365277-04-9 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-05-0 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 365277-24-3 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-34-5 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-35-6 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Page 11


L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCAPLUS  
 CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 2-propenyl ester (9CI)} (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-38-9 HCAPLUS  
 CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 1,1-dimethylethyl ester (9CI)} (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 365277-61-8 HCAPLUS  
 CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, butyl ester (9CI)} (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-63-0 HCAPLUS  
 CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 3-but enyl ester (9CI)} (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-64-1 HCAPLUS  
 CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, phenyl ester (9CI)} (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 365277-58-3 HCAPLUS  
 CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 4-bromophenyl ester (9CI)} (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-59-4 HCAPLUS

CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 4-chlorophenyl ester (9CI)} (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-60-7 HCAPLUS


CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, ethyl ester (9CI)} (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 365277-65-2 HCAPLUS  
 CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 2-methylpropyl ester (9CI)} (CA INDEX NAME)

Absolute stereochemistry.



RN 459809-96-2 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-  
 10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460070-76-2 HCAPLUS  
 CN Carbamic acid,  
 {[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 4-methoxyphenyl ester (9CI)} (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 365277-06-1 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-22-1 HCPLUS  
 CN Cholest-5-en-3-ol (3 $\beta$ )-, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]carbamate (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 4 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 365277-23-2 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-24-3 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 365277-34-5 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-35-6 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

12/13/2006

L4 ANSWER 4 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 365277-38-9 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-58-3 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-59-4 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

Page 14


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
Absolute stereochemistry.

(Continued)




RN 365277-60-7 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-61-8 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-63-0 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460073-80-7 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473974-75-3 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473974-76-4 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
naphthacenyl]-, 3-but enyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-64-1 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-65-2 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460070-76-2 HCAPLUS


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488817-33-0 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:777531 HCPLUS  
 DOCUMENT NUMBER: 139:292094  
 TITLE: Preparation of substituted tetracycline compounds for the treatment of bacterial infections and neoplasms  
 INVENTOR(S): Nelson, Mark L.; Ohemeng, Kwasi; Frechette, Roger; Abato, Paul; Assefa, Haregewein; Bandarage, Upul; Berniac, Joel; Bhattacharya, Beena; Chen, Jackson; Ismail, Mohamed Y.; Kim, Oak A.; Mathews, Jude; McIntyre, Laura; Nihlavi, Mohammed; Pearson, Andie; Reddy, Lakma; Sheahan, Paul; Sizensky, Emmanuel; Tourigny, Justin; Verma, Atul K.; Viski, Peter; Warchol, Tadeusz  
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int'l Appl., 118 pp.  
 CODEN: PIIXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003079984	A2	20031002	WO 2003-US8324	20030318
WO 2003079984	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479877	AA	20031002	CA 2003-2479877	20030318
AU 2003218243	A1	20031008	AU 2003-218243	20030318
EP 1503981	A2	20050209	EP 2003-711236	20030318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU				
JP 2005520846	T2	20050714	JP 2003-577816	20030318
CN 1653037	A	20050810	CN 2003-810965	20030318
US 2005038002	A1	20050217	US 2003-740961	20031218
PRIORITY APPLN. INFO.:			US 2002-366915P	P 20020321
			US 2002-367045P	P 20020321
			US 2002-367046P	P 20020321
			US 2002-395468P	P 20020712
			US 2003-440305P	P 20030114
			US 2003-391903	B1 20030318
			WO 2003-US8324	W 20030318

L4 ANSWER 5 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 OTHER SOURCE(S): MARPAT 139:292094  
 IT 460073-80-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of tetracycline compds. for the treatment of bacterial infections and neoplasms)  
 RN 460073-80-7 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:678826 HCPLUS  
 DOCUMENT NUMBER: 139:224449  
 TITLE: Insulin and IGF-1 receptor peptide agonists and antagonists, and therapeutic use  
 INVENTOR(S): Pillutla, Renuka; Brissette, Renee; Blume, Arthur J.; Schaffter, Laugie; Brandt, Jakob; Goldstein, Neil I.; Spetzler, Jane; Ostergaard, Soren  
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; DG1 Biotechnologies  
 SOURCE: PCT Int'l Appl., 328 pp.  
 CODEN: PIIXD2


DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070747	A2	20030828	WO 2002-US30312	20020924
WO 2003070747	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003195147	A1	20031016	US 2001-962756	20010924
US 6875741	B2	20050405		
CA 2460055	AA	20030828	CA 2002-2460055	20020924
AU 2002366384	A1	20030509	AU 2002-366384	20020924
EP 1496935	A2	20050119	EP 2002-806867	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005517741	T2	20050616	JP 2003-569654	20020924
PRIORITY APPLN. INFO.:			US 2001-962756	A2 20010924
			US 1998-146127	B2 19980902
			US 2000-538038	A2 20000329
			WO 2002-US30312	W 20020924

OTHER SOURCE(S): MARPAT 139:224449  
 IT 365277-84-5P  
 RL: BPN (Biosynthetic preparation); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (peptides from various peptide libraries, their dimers and fusion proteins as modulators of insulin and IGF-1 receptors)  
 RN 365277-84-5 HCPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-

bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, O-(4-fluorophenyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 Absolute stereochemistry.




L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:57866 HCAPLUS  
 DOCUMENT NUMBER: 138:117673  
 TITLE: Tetracycline compounds having target therapeutic activities  
 INVENTOR(S): Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham  
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc.; USA  
 SOURCE: PCT Int. Appl., 158 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003005971	A2	20030123	WO 2002-US22451	20020715
WO 2003005971	A3	20031127		
WO 2003005971	C1	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MM, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002318238	A1	20030129	AU 2002-318238	20020715
US 2004063674	A1	20040401	US 2002-196010	20020715
EP 1408987	A2	20040421	EP 2002-748169	20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004537544	T2	20041216	JP 2003-511780	20020715
US 2006194773	A1	20060831	US 2004-966119	20041122
PRIORITY APPLN. INFO.:			US 2001-305546P	P 20010713
			US 2002-395741P	P 20020712
			US 2002-196010	A2 20020715
			WO 2002-US22451	W 20020715
			US 2003-441141P	P 20030116
			US 2004-759484	B1 20040116

OTHER SOURCE(S): MARPAT 138:117673  
 IT 365277-03-8 365277-04-9 365277-05-0  
 365277-06-1 365277-22-1 365277-23-2  
 365277-24-3 365277-34-5 365277-35-6  
 365277-36-7 365277-38-9 365277-58-3  
 365277-59-4 365277-60-7 365277-61-8  
 365277-63-0 365277-64-1 365277-65-2


L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 INDEX NAME)

Absolute stereochemistry.



RN 365277-06-1 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl], 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-22-1 HCAPLUS  
 CN Cholest-5-en-3-ol (3B)-, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl] carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

459809-96-2 460070-76-2 460073-80-7

473974-75-3 473974-76-4 488817-33-0

RL: PA (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USEs (Uses)


(tetracycline compds. with target therapeutic activities)

RN 365277-03-8 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-04-9 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-05-0 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-


(dimethylamino)-5,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A

L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B




RN 365277-23-2 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-24-3 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-


L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-34-5 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-35-6 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 365277-59-4 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-60-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-61-8 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)


12/13/2006

L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 365277-36-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-38-9 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-58-3 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 365277-63-0 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butene-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-64-1 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-65-2 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459809-96-2 HCPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460070-76-2 HCPLUS  
CN Carbamic acid, [(5aP,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-80-7 HCPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-


L4 ANSWER 7 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
ACCESSION NUMBER: 2002-832571 HCPLUS  
DOCUMENT NUMBER: 137:333118  
TITLE: Substituted tetracycline compounds for the treatment of malaria

INVENTOR(S): Draper, Michael; Nelson, Mark L.; Frechette, Roger  
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 89 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:




L4 ANSWER 7 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
naphthacenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473974-75-3 HCPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473974-76-4 HCPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 488817-33-0 HCPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-

ACCESSION NUMBER: 2002-832571 HCPLUS  
DOCUMENT NUMBER: 137:333118  
TITLE: Substituted tetracycline compounds for the treatment of malaria  
INVENTOR(S): Draper, Michael; Nelson, Mark L.; Frechette, Roger  
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 89 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085303	A2	20021031	WO 2002-US12935	20020424
WO 2002085303	A3	20030515		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BU, CF, CG, CI, CM, GA, GN, GO, GM, MR, NE, SN, TD, TG				
CA 2444899	AA	20021031	CA 2002-2444899	20020424
EP 1399414	A2	20040324	EP 2002-723955	20020424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529927	T2	20040930	JP 2002-582879	20020424
PRIORITY APPLN. INFO.:			US 2001-286193P	P 20010424
			WO 2002-US12935	W 20020424

OTHER SOURCE(S): MARPAT 137:333118  
IT 365277-22-1 365277-23-2 365277-38-9  
365277-59-4 365277-60-7 365277-63-0  
473974-75-3 473974-76-4  
RL: PAG (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Substituted tetracycline compds. for the treatment of malaria)  
RN 365277-22-1 HCPLUS  
CN Cholest-5-en-3-ol (3 $\beta$ )-, [(5R,5aS,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]carbamate (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 365277-23-2 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-63-0 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butenoyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473974-75-3 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473974-76-4 HCAPLUS


CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 365277-38-9 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-59-4 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-60-7 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Andrew Freistein 10/786, 710

L4 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:716234 HCAPLUS  
 DOCUMENT NUMBER: 137:247552  
 TITLE: Preparation of 7, 9-substituted tetracycline derivatives for pharmaceutical use as antibacterial agents  
 INVENTOR(S): Nelson, Mark L.; Frechette, Roger; Viski, Peter;  
 Ismail, Mohamed; Bowser, Todd; McIntyre, Laura;  
 Bhateria, Beena; Hawkins, Paul; Reddy, Lakshmi;  
 Stapleton,  
 PATENT ASSIGNEE(S): Karen, Marchol, Tad; Sheahan, Paul  
 Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 54 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072532	A1	20020919	WO 2001-US20722	20010629
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2440383	AA	20020919	CA 2001-2440383	20010629
US 2002153354	A1	20021219	US 2001-895797	20010629
US 6693068	B2	20040127		
EP 1368305	A1	20031210	EP 2001-950651	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200402047	A2	20050128	HU 2004-2047	20010629
JP 2005506291	T2	20050303	JP 2002-571448	20010629
BR 2001016935	A	20050412	BR 2001-16935	20010629
ZA 2003007239	A	20041117	ZA 2003-7239	20030516
US 2004138183	A1	20040715	US 2003-738862	20031216
PRIORITY APPLN. INFO.:			US 2001-275620P	P 20010313
		US 2001-895797	A1 20010629	
		WO 2001-US20722	W 20010629	

OTHER SOURCE(S): MARPAT 137:247552  
 IT 459809-96-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

L4 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:716035 HCAPLUS  
 DOCUMENT NUMBER: 137:244598  
 TITLE: Substituted tetracycline compounds as synergistic antifungal agents  
 INVENTOR(S): Draper, Michael; Nelson, Mark L.  
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 114 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072031	A2	20020919	WO 2002-US7829	20020314
WO 2002072031	A3	20031113		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, QO, GW, ML, MR, NE, SN, TD, TG				
CA 2440757	AA	20020919	CA 2002-2440757	20020314
US 2003166585	A1	20030904	US 2002-97634	20020314
US 7045507	B2	20060516		
EP 1381372	A2	20040121	EP 2002-750617	20020314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005504722	T2	20050217	JP 2002-570991	20020314
US 2005070510	A1	20050331	US 2004-943571	20040916
PRIORITY APPLN. INFO.:			US 2001-275899P	P 20010314
		US 2002-97634	A1 20020314	
		WO 2002-US7829	W 20020314	


OTHER SOURCE(S): MARPAT 137:244598  
 IT 365277-03-8 365277-07-2 365277-23-2  
 365277-35-6 365277-36-7 365277-38-9  
 365277-60-7 365277-61-8 365277-63-0  
 365277-65-2 459809-96-2 460070-76-2  
 460073-80-7  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)  
 RN 365277-03-8 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

12/13/2006


L4 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 459809-96-2 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 365277-07-2 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-23-2 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-35-6 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-

-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI)


(CA INDEX NAME)

Absolute stereochemistry.

12/13/2006 Page 21

L4 ANSWER 10 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-36-7 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 365277-38-9 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 10 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 365277-65-2 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459809-96-2 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460070-76-2 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 365277-60-7 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-61-8 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-63-0 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-but enyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 10 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 460073-80-7 HCPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:716027 HCAPLUS  
 DOCUMENT NUMBER: 137:244597  
 TITLE: Substituted tetracycline compounds as antifungal agents  
 INVENTOR(S): Draper, Michael; Nelson, Mark L.  
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 71 pp.  
 CODEN: PIKXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072022	A2	20020919	WO 2002-US7502	20020314
WO 2002072022	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457234	AA	20020919	CA 2002-2457234	20020314
US 2003100017	A1	20030529	US 2002-97457	20020314
US 6841546	B2	20050111		
EP 1379255	A2	20040114	EP 2002-721365	20020314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004530661	T2	20041007	JP 2002-570982	20020314
US 2005020545	A1	20050127	US 2004-921580	20040818
			US 2001-275948P	P 20010314
PRIORITY APPLN. INFO.:				
		US 2002-97457	A3 20020314	
		WO 2002-US7502	W 20020314	

OTHER SOURCE(S): MARPAT 137:244597  
 IT 365277-36-7  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)  
 RN 365277-36-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:51419 HCAPLUS  
 DOCUMENT NUMBER: 136:102231  
 TITLE: Preparation of 9-substituted minocycline derivatives for pharmaceutical use as antibacterial agents  
 INVENTOR(S): Nelson, Mark L.; Frechette, Roger; Viski, Peter; Ismail, Mohamed; Bowser, Todd; Dumornay, Jimmy; Rennie, Glen; Liu, Gui; Koza, Darrell; Sheahan, Paul; Stapleton, Karen; Hawkins, Paul; Bhatia, Beena; Verma, Atul; McIntyre, Laura; Warchol, Tad  
 PATENT ASSIGNEE(S): Trustees of Tufts College, USA; Paratek Pharmaceuticals, Inc.  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIKXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004406	A2	20020117	WO 2001-US20721	20010629
WO 2002004406	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, LT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2415178	AA	20020117	CA 2001-2415178	20010629
EP 1301467	A2	20030416	EP 2001-965828	20010629
EP 1301467	B1	20060816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012269	A	20030701	BR 2001-12269	20010629
US 2003125348	A1	20030703	US 2001-89587	20010629
US 6846939	B2	20050125		
HU 200301169	A2	20030828	HU 2003-1169	20010629
JP 2004502752	T2	20040129	JP 2002-509074	20010629
CN 1690047	A	20051102	CN 2005-10053044	20010629
EP 1679305	A1	20060712	EP 2006-7501	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 336481	E	20060915	AT 2001-965828	20010629
ZA 2003000749	A	20050628	ZA 2003-749	20030128
US 2005026876	A1	20050203	US 2004-786881	20040224
US 2004214801	A1	20041028	US 2004-839023	20040504
AU 2005201623	A1	20050505	AU 2005-201623	20050418
PRIORITY APPLN. INFO.:			US 2000-216559P	P 20000707
			US 2001-275621P	P 20010313
			AU 2001-86388	A3 20010629
			CN 2001-815087	A3 20010629

L4 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

EP 2001-965828	A3 20010629
US 2001-895857	A2 20010629
WO 2001-US20721	W 20010629
US 2002-362654P	P 20020308
US 2002-395495P	P 20020712
US 2003-384855	B2 20030310
US 2003-412656	B1 20030410

OTHER SOURCE(S): MARPAT 136:102231  
 IT 365277-07-2P 365277-36-7P 365277-38-9P  
 365277-58-3P 365277-59-4P 365277-60-7P  
 365277-61-8P 365277-63-OP 365277-64-1P  
 365277-65-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 9-substituted minocycline derivs. for pharmaceutical use as antibacterial agents)

RN 365277-07-2 HCAPLUS


CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-

5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-


naphthalenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCAPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-38-9 HCPLUS  
CN Carbamic acid,  
[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.



RN 365277-58-3 HCPLUS  
CN Carbamic acid,  
[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 365277-59-4 HCPLUS  
CN Carbamic acid,  
[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-


L4 ANSWER 12 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
CN Carbamic acid,  
[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
naphthacenyl]-, 3-butynyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 365277-64-1 HCPLUS  
CN Carbamic acid,  
[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 365277-65-2 HCPLUS  
CN Carbamic acid,  
[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.



L4 ANSWER 12 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 365277-60-7 HCPLUS

CN Carbamic acid,  
[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 365277-61-8 HCPLUS

CN Carbamic acid,  
[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.



RN 365277-63-0 HCPLUS

L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:747739 HCPLUS

DOCUMENT NUMBER: 135:288637

TITLE: Preparation of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivatives for pharmaceutical use as antibiotics

INVENTOR(S): Nelson, Mark L.; Levy, Stuart B.; Prechette, Roger; Bowser, Todd E.; Ismail, Mohamed Y.

PATENT ASSIGNEE(S): Trustees of Tufts College, USA

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074761	A1	20011011	WO 2001-US10342	20010330
W: AE, AG, AL, AM, AT, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, VN, YU, ZA,				
ZW				
RW: GH, GM, KE, LS, MM, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GM, ML, MR, NE, SN, TD, TG				
CA 2404628	AA	20011011	CA 2001-2404628	20010330
AU 2001051157	A5	20011015	AU 2001-51157	20010330
US 2002103171	A1	20020801	US 2001-823884	20010330
US 6818634	B2	20041116		
EP 1272459	A1	20030101	EP 2001-924508	20010330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009725	A	20031024	BR 2001-9725	20010330
HU 200300082	A2	20030528	HU 2003-82	20010330
JP 2004505012	T2	20040219	JP 2001-572456	20010330
US 2002128237	A1	20020912	US 2001-882273	20010615
US 2002147182	A1	20021010	US 2001-895796	20010629
US 6500812	B2	20021231		
ZA 2002008735	A	20031029	ZA 2002-8735	20021029
US 2004176334	A1	20040909	US 2004-786710	20040224
US 2004224927	A1	20041111	US 2004-820456	20040407
US 2006234988	A1	20061019	US 2006-453326	20060614
PRIORITY APPLN. INFO.:				
			US 2000-193879P	P 20000331
			US 2000-193972P	P 20000331
			US 2001-280367P	P 20010329
			US 1999-154701P	P 19990914
			US 2000-204158P	P 20000515
			US 2000-212030P	P 20000616
			US 2000-212139P	P 20000616


L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 US 2000-212471P P 20000616  
 WO 2000-US16672 W 20000616  
 US 2000-216580P P 20000707  
 US 2001-823884 A1 20010330  
 WO 2001-US10342 W 20010330  
 US 2001-882273 B1 20010615  
 US 2004-820456 B1 20040407

## OTHER SOURCE(S): MARPAT 135:288637

IT 365277-03-0P 365277-04-9P 365277-05-0P  
 365277-06-1P 365277-07-2P 365277-22-1P  
 365277-23-2P 365277-24-3P 365277-34-5P  
 365277-35-6P 365277-36-7P 365277-38-9P  
 365277-58-3P 365277-59-4P 365277-60-7P  
 365277-61-8P 365277-63-0P 365277-64-1P  
 365277-65-2P 365277-66-5P 365277-71-0P  
 365277-80-4P 365277-84-5P 365277-85-6P  
 365277-86-7P 365277-87-8P 365280-21-3P  
 RL: BAC (Biological activity or effect, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and  
 heteroaryl-amino substituted tetracycline derivs. for pharmaceutical  
 use as antibiotics)

RN 365277-03-8 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI)  
 (CA INDEX NAME)


## Absolute stereochemistry.



L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 365277-07-2 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-22-1 HCPLUS  
 CN Cholest-5-en-3-ol (3B)-, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]carbamate (9CI) (CA INDEX NAME)

## Absolute stereochemistry.


PAGE 1-A



12/13/2006


L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 365277-04-9 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA  
 INDEX NAME)

## Absolute stereochemistry.



RN 365277-05-0 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA  
 INDEX NAME)


## Absolute stereochemistry.



RN 365277-06-1 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA  
 INDEX NAME)


## Absolute stereochemistry.

L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 PAGE 1-B



RN 365277-23-2 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI)  
 (CA INDEX NAME)

## Absolute stereochemistry.



RN 365277-24-3 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methylphenyl ester (9CI) (CA  
 INDEX NAME)

## Absolute stereochemistry.




RN 365277-34-5 HCPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-p

Page 25


L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 S-methyl-10,12-dioxo-2-naphthacenyl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-35-6 HCAPLUS  
 CN Carbamic acid, [(5R,6aS,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 365277-60-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-61-8 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-63-0 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 365277-38-9 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-58-3 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-59-4 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 365277-64-1 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-65-2 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-68-5 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-71-0 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-80-1 HCAPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, O-(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-86-7 HCAPLUS  
 CN Carbamothioic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, O-(2,2-dimethylpropyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-87-8 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, pentyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365280-21-3 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1-methylethenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

12/13/2006




RN 365277-84-5 HCAPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, O-(4-fluorophenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-85-6 HCAPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, O-(4-methoxyphenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1997-327 HCAPLUS  
 DOCUMENT NUMBER: 126:31223  
 TITLE: Preparation of novel tetracycline derivatives  
 INVENTOR(S): Vu, Chi Bao  
 PATENT ASSIGNEE(S): Pfizer, Inc., USA; Vu, Chi Bao  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9634852	A1	19961107	WO 1996-IB335	19960417
W: AU, CA, JP, MX, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NC, NL, PT,				
CA 2219277	AA	19961107	CA 1996-2219277	19960417
AU 9651186	A1	19961121	AU 1996-51186	19960417
AU 693013	B2	19980618		
EP 823893	A1	19980218	EP 1996-907639	19960417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
JP 11504916	T2	19990511	JP 1996-533149	19960417
US 6165999	A	20001226	US 1998-945775	19980223
PRIORITY APPLN. INFO.:			US 1995-433102	A 19950503
		WO 1996-IB335		W 19960417

OTHER SOURCE(S): MARPAT 126:31223  
 IT 184593-66-6P 184593-69-9P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of antibacterial tetracycline derivs.)  
 RN 184593-66-6 HCAPLUS  
 CN Carbamic acid,  
 (9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-  
 octahydro-1,5,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-,  
 methyl ester, [5S-(5a,5aB,6aB,7B,10aB)]- (9CI)  
 (CA INDEX NAME)


## Absolute stereochemistry.



L4 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1995:55081 HCAPLUS  
 DOCUMENT NUMBER: 122:188050  
 TITLE: "Glycylcyclines". 3. 9-Aminodoxycyclinecarboxamides  
 AUTHOR(S): Barden, Timothy C.; Buckwalter, Brian L.; Testa, Raymond T.; Petersen, Peter J.; Lee, Ving J.  
 CORPORATE SOURCE: Agricultural Research Division, American Cyanamid Company, Princeton, NJ, 08543-0400, USA  
 SOURCE: Journal of Medicinal Chemistry (1994), 37(20), 3205-11  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 161452-40-OP  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and bactericidal activity of acylaminodoxycyclines)

RN 161452-40-0 HCAPLUS  
 CN Carbamic acid,  
 (9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-  
 octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-,  
 methyl ester, [5R-(5a,5aB,6a,6aB,7a,10aB).alpha.  
 a.]- (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



L4 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 184593-69-9 HCAPLUS  
 CN Carbamic acid,  
 (9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-  
 octahydro-1,5,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-,  
 Phenyl ester, [5S-(5a,5aB,6aB,7B,10aB)]- (9CI)  
 (CA INDEX NAME)

## Absolute stereochemistry.



L4 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1994:579403 HCAPLUS  
 DOCUMENT NUMBER: 121:179403

TITLE: Preparation of 7-(substituted)-8-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines

as  
 INVENTOR(S): Sum, Phak Eng; Lee, Ving J.; Hlavka, Joseph J.;  
 TESTA, Raymond T.  
 PATENT ASSIGNEE(S): American Cyanamid Co., USA  
 SOURCE: Eur. Pat. Appl., 181 pp.  
 DOCUMENT TYPE: EPXXWD  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 582810	A1	19940216	EP 1993-109850	19930621
EP 582810	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 215530	E	20020415	AT 1993-109850	19930621
PT 582810	T	20020830	PT 1993-109850	19930621
ES 2173876	T3	19991011	ES 1993-109850	19930621
CZ 289195	B6	20011114	CZ 1993-1575	19930804
SK 281871	B6	20010806	SK 1993-857	19930809
CA 2103861	AA	19940214	CA 1993-2103861	19930811
CA 2103861	C	20040727		
JP 06228072	A2	19940816	JP 1993-217927	19930811
JP 3639313	B2	20050420		
NO 9302872	A	19940214	NO 1993-2872	19930812
AU 9344601	A1	19940217	AU 1993-44601	19930812
AU 674524	B2	19970102		
ZA 9305892	A	19940310	ZA 1993-5892	19930812
HU 64945	A2	19940328	HU 1993-2333	19930812
HU 213269	B	19970428		
IL 106677	A1	19980615	IL 1993-106677	19930812
PL 174022	B1	19980630	PL 1993-300066	19930812
PL 174127	B1	19980630	PL 1993-318908	19930812
PL 174230	B1	19980731	PL 1993-316767	19930812
IL 119750	A1	19980924	IL 1993-119750	19930812
IL 119751	A1	19980924	IL 1993-119751	19930812
PL 175487	B1	19990129	PL 1993-316768	19930812
RU 2127255	C1	19990310	RU 1993-48636	19930812
CN 1090267	A	19940803	CN 1993-109819	19930813
CN 1048719	B	20000126		
US 5430162	A	19950704	US 1994-214992	19940321
US 5495018	A	19960227	US 1994-352407	19941208
US 5886175	A	19990323	US 1994-352310	19941208
US 5512553	A	19960430	US 1995-454966	19950531
PRIORITY APPLN. INFO.:			US 1992-928588	A 19920813
			IL 1993-106677	A3 19930812
			US 1994-214992	B3 19940321

OTHER SOURCE(S): MARPAT 121:179403  
 IT 157579-07-2P 157579-18-5P 157579-22-1P  
 157579-23-2P 157579-28-7P 157579-29-BP

L4 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 157579-30-1P 157579-31-2P 157579-36-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); prepn. of, as antibiotic)


RN 157579-07-2 HCAPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-3-chloro-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester, [5aR-(5a<sup>u</sup>,6a<sup>u</sup>,7<sup>a</sup>,10a.<sup>alpha</sup>.<sup>beta</sup>.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157579-18-5 HCAPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-7-(dimethylamino)-3-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester, [5aR-(5a<sup>u</sup>,6a<sup>u</sup>,7<sup>a</sup>,10a.<sup>alpha</sup>.<sup>beta</sup>.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157579-22-1 HCAPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-3-chloro-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-(dimethylamino)ethyl ester, monohydrochloride, [5aR-(5a<sup>u</sup>,6a<sup>u</sup>,7<sup>a</sup>,10a<sup>u</sup>.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 157579-29-8 HCAPLUS  
 CN Methanesulfonic acid, trifluoro-, 8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-3-[(methoxycarbonyl)amino]-5,7-dioxo-2-naphthacenyl ester, [6aS-(6a<sup>u</sup>,10<sup>a</sup>,10a<sup>u</sup>,11a<sup>u</sup>.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157579-30-1 HCAPLUS  
 CN 2-Naphthacencarboxamide, 8-chloro-4-(dimethylamino)-9-[(dimethylamino)oxy]carbonylamino]-1,4,4a,5,5a,6,11,12a-octahydro-10,12a-tetrahydroxy-1,8,10a,11-dioxo-, [4S-(4a<sup>u</sup>,5a<sup>u</sup>,12a<sup>u</sup>.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157579-31-2 HCAPLUS  
 CN 2-Naphthacencarboxamide, 8-chloro-9-[(dimethylamino)oxy]carbonylamino)-

12/13/2006 4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-


L4 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 157579-23-2 HCAPLUS  
 CN 2-Naphthacencarboxamide, 8-chloro-9-[(dimethylamino)oxy]carbonylamino)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4a<sup>u</sup>,5a<sup>u</sup>,12a<sup>u</sup>.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 157579-28-7 HCAPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-7-(dimethylamino)-3-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester, monohydrochloride, [5aR-(5a<sup>u</sup>,6a<sup>u</sup>,7<sup>a</sup>,10a<sup>u</sup>.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 1,11-dioxo-, [4S-(4a<sup>u</sup>,5a<sup>u</sup>,12a<sup>u</sup>.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157579-36-7 HCAPLUS

CN Carbamic acid, [9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-3-iodo-10,12-dioxo-2-naphthacenyl]-, methyl ester, [5aR-(5a<sup>u</sup>,6a<sup>u</sup>,7<sup>a</sup>,10a<sup>u</sup>.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157579-37-8 HCAPLUS

CN Carbamic acid, [9-(aminocarbonyl)-3-bromo-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester, [5aR-(5a<sup>u</sup>,6a<sup>u</sup>,7<sup>a</sup>,10a<sup>u</sup>.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 17 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993-603237 HCPLUS

DOCUMENT NUMBER: 119:203237

TITLE: Preparation of 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines  
 INVENTOR(S): Hlavka, Joseph J.; Sum, Phaik Eng; Gluzman, Yakov; Lee, Ving J.; Ross, Adma A.  
 PATENT ASSIGNEE(S): American Cyanamid Co., USA  
 SOURCE: Eur. Pat. Appl., 209 pp.

CODEN: EPXKOW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 536515	A1	19920414	EP 1992-114281	19920821
EP 536515	B1	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 211128	E	20020115	AT 1992-114281	19920821
PT 536515	T	20020531	PT 1992-114281	19920821
ES 2168254	T3	20020616	ES 1992-114281	19920821
HU 63145	A2	19930728	HU 1992-3110	19920930
HU 219973	B	20011028		
CZ 284159	B6	19980812	CZ 1992-2984	19920930
CZ 284209	B6	19980916	CZ 1997-3093	19920930
SK 280837	B6	20000814	SK 1992-2984	19920930
SK 284826	B6	20050120	SK 1999-1149	19920930
IL 103320	A1	19980120	IL 1992-103320	19921001
IL 119590	A1	19990312	IL 1992-119590	19921001
CA 2079692	AA	19930405	CA 1992-2079692	19921002
CA 2079692	C	20040608		
NO 9203857	A	19930405	NO 1992-3857	19921002
NO 301472	B1	19971103		
AU 9226183	A1	19930408	AU 1992-26183	19921002
AU 654049	B2	19941020		
ZR 9207607	A	19930413	ZR 1992-7607	19921002
PL 172282	B1	19970829	PL 1992-310717	19921002
PL 173311	B1	19980827	PL 1992-296143	19921002
PL 175957	B1	19990331	PL 1992-310718	19921002
PL 176333	B1	19990531	PL 1992-310719	19921002
FI 114911	B1	20050131	FI 1992-4454	19921002
ON 1072172	A	19930519	CN 1992-112130	19921003
CN 1048240	B	20000112		
JP 052555219	A2	19931005	JP 1992-288114	19921005
JP 3186663	B2	20010711		
US 5494903	A	19960227	US 1994-286096	19940804
US 5529990	A	19960625	US 1995-455446	19950531
US 5530117	A	19960625	US 1995-455923	19950531
HK 1011348	A1	20020412	HK 1998-112374	19981127
			US 1991-771376	A 19911004
PRIORITY APPLN. INFO.:				
		US 1992-926091	B1 19920813	
		IL 1992-103320	A3 19921001	

L4 ANSWER 17 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 150251-75-5 HCPLUS

CN Carbamic acid, [9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, methyl ester, [(5R-(5a,5a,6a,7a,10a))- (SC1) (CA INDEX NAME)]


Absolute stereochemistry.



RN 150251-76-6 HCPLUS

CN Carbamic acid, [9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-(diethylamino)ethyl ester, [(5R-(5a,5a,6a,7a,10a))- (SC1) (CA INDEX NAME)]

Absolute stereochemistry.



RN 150251-77-7 HCPLUS

CN Carbamic acid, [9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, ethenyl ester, [(5R-(5a,5a,6a,7a,10a))- (SC1) (CA INDEX NAME)]


12/13/2006

L4 ANSWER 17 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
US 1994-286096 A3 19940804

OTHER SOURCE(S): MARPAT 119:203237

IT 150231-22-4P 150231-23-5P 150251-75-5P  
150251-76-6P 150251-77-7P 150251-78-8P150521-69-OP 150521-70-3P  
PL: BAC (Biological activity or effector, except adverse): BSU  
(study, unclassified): SPN (Synthetic preparation); BIOL (Biologicalstudy); PREP (Preparation)  
(preparation of, as antibacterial)RN 150231-22-4 HCPLUS  
CN Carbamic acid, [9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-(diethylamino)ethyl ester, monohydrochloride, [(5R-(5a,5a,6a,7a,10a))- (SC1) (CA INDEX NAME)]

Absolute stereochemistry.




● HCl


RN 150231-23-5 HCPLUS

CN Carbamic acid, [9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester, monohydrochloride, [(5R-(5a,5a,6a,7a,10a))- (SC1) (CA INDEX NAME)]

Absolute stereochemistry.

L4 ANSWER 17 OF 17 HCPLUS COPYRIGHT 2006 ACS on STN (Continued)  
n,10aa) - (SC1) (CA INDEX NAME)


Absolute stereochemistry.



RN 150251-78-8 HCPLUS

CN Carbamic acid, [9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester, [(5R-(5a,5a,6a,7a,10a))- (SC1) (CA INDEX NAME)]

Absolute stereochemistry.




RN 150251-79-5 HCPLUS

CN Carbamic acid, [9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, methyl ester, [(5R-(5a,5a,6a,7a,10a))-, sulfate (salt) (SC1) (CA INDEX NAME)]

CM 1

CRN 150251-75-5  
CMF C26 H32 N4 O9

Absolute stereochemistry.



Andrew Freistein 10/786, 710

L4 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 7664-93-9  
CMF H2 O4 S




RN 150521-70-3 HCAPLUS  
CN Carbanic acid, [5-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthalenyl]-, ethenyl ester, [5R-(5a,5au,6au,7a,10ad)]-, sulfate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 150251-77-7  
CMF C27 H32 N4 O9

Absolute stereochemistry.



CM 2

CRN 7664-93-9  
CMF H2 O4 S



Andrew Freistein 10/786,710

=> file reg  
COST IN U.S. DOLLARS  
SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 67.26 234.41

FILE 'REGISTRY' ENTERED AT 13:03:54 ON 13 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 DEC 2006 HIGHEST RN 915277-53-1  
DICTIONARY FILE UPDATES: 12 DEC 2006 HIGHEST RN 915277-53-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10786710\d2.str



chain nodes :

18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 35 36

chain bonds :

1-19 2-30 9-18 12-28 13-27 14-20 15-21 16-22 17-26 20-23 20-24 22-25

22-29 30-31 31-32 31-33

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-35 6-9 7-10 7-8 7-36 8-9 8-13 10-11 11-12

11-14 12-13 12-17 14-15 15-16 16-17 35-36

exact/norm bonds :

1-19 2-30 5-35 6-9 7-10 7-8 7-36 8-9 8-13 9-18 10-11 11-12 11-14 12-13

12-17 12-28 13-27 14-15 14-20 15-16 15-21 16-17 17-26 20-23 20-24 22-25

22-29 30-31 31-32 31-33 35-36

exact bonds :

16-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G2:O,S

Andrew Freistein 10/786,710

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS  
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:Atom

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR



G1

G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 13:04:14 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 4 TO 200  
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> s 15 full

Andrew Freistein 10/786,710

FULL SEARCH INITIATED 13:04:18 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 82 TO ITERATE



100.0% PROCESSED 82 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

L7 0 SEA SSS FUL L5

=>

Uploading C:\Program Files\Stnexp\Queries\10786710\d2b.str



chain nodes :

18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 35

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 33 34

chain bonds :

1-19 2-30 9-18 12-28 13-27 14-20 15-21 16-22 17-26 20-23 20-24 22-25

22-29 30-31 31-32 31-35

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-33 6-9 7-10 7-8 7-34 8-9 8-13 10-11 11-12  
11-14 12-13 12-17 14-15 15-16 16-17 33-34

exact/norm bonds :

1-19 2-30 5-33 6-9 7-10 7-8 7-34 8-9 8-13 9-18 10-11 11-12 11-14 12-13  
12-17 12-28 13-27 14-15 14-20 15-16 15-21 16-17 17-26 20-23 20-24 22-25  
22-29 30-31 31-32 31-35 33-34

Andrew Freistein 10/786,710



exact bonds :  
16-22  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS  
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:Atom 35:CLASS

L8 STRUCTURE UPLOADED

=>  
Uploading C:\Program Files\Stnexp\Queries\10786710\d2c.str



chain nodes :  
18 19 20 21 22 23 24 25 26 27 28 29 30 33

Andrew Freistein 10/786,710

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 31 32

chain bonds :

1-19 2-28 9-18 12-26 13-25 14-20 15-21 16-22 17-24 22-23 22-27 28-29

29-30 29-33

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-31 6-9 7-10 7-8 7-32 8-9 8-13 10-11 11-12

11-14 12-13 12-17 14-15 15-16 16-17 31-32

exact/norm bonds :

1-19 2-28 5-31 6-9 7-10 7-8 7-32 8-9 8-13 9-18 10-11 11-12 11-14 12-13

12-17 12-26 13-25 14-15 14-20 15-16 15-21 16-17 17-24 22-23 22-27 28-29

29-30 29-33 31-32

exact bonds :

16-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS

20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS


28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:Atom 33:CLASS

L9 STRUCTURE UPLOADED

=> d

L9 HAS NO ANSWERS

L9 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

Andrew Freistein 10/786,710

=> s 19  
SAMPLE SEARCH INITIATED 13:05:49 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5 TO 234  
PROJECTED ANSWERS: 0 TO 0



L10 0 SEA SSS SAM L9

=> s 19 full  
FULL SEARCH INITIATED 13:05:53 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 92 TO ITERATE

100.0% PROCESSED 92 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L9

=>  
Uploading C:\Program Files\Stnexp\Queries\10786710\db.str



chain nodes :

19 20 21 22 23 24 25 26 27 28 30 31 32 33

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-20 2-30 10-19 13-27 14-26 15-21 16-22 17-23 18-25 23-24 23-28 30-31

31-32 31-33

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13

12-15 13-14 13-18 15-16 16-17 17-18

exact/norm bonds :

1-20 2-30 5-7 6-10 7-8 8-9 8-11 9-10 9-14 10-19 11-12 12-13 12-15

13-14 13-18 13-27 14-26 15-16 15-21 16-17 16-22 17-18 17-23 18-25 23-24

23-28 30-31 31-32 31-33

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S,N

G2:O,S

Andrew Freistein 10/786,710

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS  
28:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS

L12 STRUCTURE UPLOADED

=> d

L12 HAS NO ANSWERS

L12 STR



G1 C,O,S,N

G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s 112

SAMPLE SEARCH INITIATED 13:06:58. FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS  
SEARCH TIME: 00.00.01

3 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3 TO 163  
PROJECTED ANSWERS: 3 TO 163

L13 3 SEA SSS SAM L12

=> s 112 full

FULL SEARCH INITIATED 13:07:02 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 73 TO ITERATE

Andrew Freistein 10/786,710

100.0% PROCESSED 73 ITERATIONS  
SEARCH TIME: 00.00.01

55 ANSWERS

L14 55 SEA SSS FUL L12

=> file hcaplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
501.70 736.11

FILE 'HCAPLUS' ENTERED AT 13:07:05 ON 13 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Dec 2006 VOL 145 ISS 25  
FILE LAST UPDATED: 12 Dec 2006 (20061212/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 114  
L15 17 L14

=>

---Logging off of STN---

=>  
Executing the logoff script...

=> LOG Y  
  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
2.53 738.64

STN INTERNATIONAL LOGOFF AT 13:07:35 ON 13 DEC 2006